,address1,address2,city,state,zip,country,phone,website,industry,industryDisp,sector,sectorDisp,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,impliedSharesOutstanding,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,52WeekChange,SandP52WeekChange,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,uuid,messageBoardId,gmtOffSetMilliseconds,currentPrice,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,The Pennzoil Building,Suite 1300 North Tower 700 Milam,Houston,TX,77002,United States,410 350 1839,https://www.anthera.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",21,"{'maxAge': 1, 'name': 'Mr. Paul F. Truex M.B.A., MBA', 'age': 53, 'title': 'Exec. Chairman', 'yearBorn': 1969, 'fiscalYear': 2017, 'totalPay': 100000, 'exercisedValue': 0, 'unexercisedValue': 0}",1514678400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,-123.55394,-6.493506e-05,200,200,1121,6950,6950,617832,0.0001,0.008,0.000258,0.0001395,0.0,0.0,USD,-8083382,0.0,26133226,26179300,2015026,1428680,1526342400,1529020800,0.077,0.0,0.0,2.09,0.104499996,6178319872,0.209,0.00047846886,1514678400,1546214400,1522454400,-24931000,-0.01,-1.54,1:8,1493596800,0.222,0.0,0.14113986,PNK,EQUITY,ANTH,ANTH,ANTHERA PHARMACEUTICALS INC,"Anthera Pharmaceuticals, Inc.",1267453800,America/New_York,EDT,7c61d184-c1c3-38af-ae8a-007492657057,finmb_20805580,-14400000,0.0001,none,8086000,0.309,-36402000,0,3.056,3.303,-1.4196299,-5.68847,-28494000,-17919376,-31952000,0.0,0.0,0.0,USD,
1,The Pennzoil Building,Suite 1300 North Tower 700 Milam,Houston,TX,77002,United States,410 350 1839,https://www.anthera.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",21,"{'maxAge': 1, 'name': 'Mr. John Craig Thompson', 'age': 55, 'title': 'CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2017, 'totalPay': 715300, 'exercisedValue': 0, 'unexercisedValue': 0}",1514678400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,-123.55394,-6.493506e-05,200,200,1121,6950,6950,617832,0.0001,0.008,0.000258,0.0001395,0.0,0.0,USD,-8083382,0.0,26133226,26179300,2015026,1428680,1526342400,1529020800,0.077,0.0,0.0,2.09,0.104499996,6178319872,0.209,0.00047846886,1514678400,1546214400,1522454400,-24931000,-0.01,-1.54,1:8,1493596800,0.222,0.0,0.14113986,PNK,EQUITY,ANTH,ANTH,ANTHERA PHARMACEUTICALS INC,"Anthera Pharmaceuticals, Inc.",1267453800,America/New_York,EDT,7c61d184-c1c3-38af-ae8a-007492657057,finmb_20805580,-14400000,0.0001,none,8086000,0.309,-36402000,0,3.056,3.303,-1.4196299,-5.68847,-28494000,-17919376,-31952000,0.0,0.0,0.0,USD,
2,The Pennzoil Building,Suite 1300 North Tower 700 Milam,Houston,TX,77002,United States,410 350 1839,https://www.anthera.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",21,"{'maxAge': 1, 'name': 'Ms. May  Liu', 'age': 46, 'title': 'Sr. VP of Fin. & Admin. and Principal Accounting Officer', 'yearBorn': 1976, 'fiscalYear': 2016, 'exercisedValue': 0, 'unexercisedValue': 0}",1514678400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,-123.55394,-6.493506e-05,200,200,1121,6950,6950,617832,0.0001,0.008,0.000258,0.0001395,0.0,0.0,USD,-8083382,0.0,26133226,26179300,2015026,1428680,1526342400,1529020800,0.077,0.0,0.0,2.09,0.104499996,6178319872,0.209,0.00047846886,1514678400,1546214400,1522454400,-24931000,-0.01,-1.54,1:8,1493596800,0.222,0.0,0.14113986,PNK,EQUITY,ANTH,ANTH,ANTHERA PHARMACEUTICALS INC,"Anthera Pharmaceuticals, Inc.",1267453800,America/New_York,EDT,7c61d184-c1c3-38af-ae8a-007492657057,finmb_20805580,-14400000,0.0001,none,8086000,0.309,-36402000,0,3.056,3.303,-1.4196299,-5.68847,-28494000,-17919376,-31952000,0.0,0.0,0.0,USD,
3,The Pennzoil Building,Suite 1300 North Tower 700 Milam,Houston,TX,77002,United States,410 350 1839,https://www.anthera.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",21,"{'maxAge': 1, 'name': 'Dr. Paul  Adams Ph.D.', 'age': 59, 'title': 'Sr. VP of Global Regulatory Affairs and Compliance', 'yearBorn': 1963, 'exercisedValue': 0, 'unexercisedValue': 0}",1514678400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,-123.55394,-6.493506e-05,200,200,1121,6950,6950,617832,0.0001,0.008,0.000258,0.0001395,0.0,0.0,USD,-8083382,0.0,26133226,26179300,2015026,1428680,1526342400,1529020800,0.077,0.0,0.0,2.09,0.104499996,6178319872,0.209,0.00047846886,1514678400,1546214400,1522454400,-24931000,-0.01,-1.54,1:8,1493596800,0.222,0.0,0.14113986,PNK,EQUITY,ANTH,ANTH,ANTHERA PHARMACEUTICALS INC,"Anthera Pharmaceuticals, Inc.",1267453800,America/New_York,EDT,7c61d184-c1c3-38af-ae8a-007492657057,finmb_20805580,-14400000,0.0001,none,8086000,0.309,-36402000,0,3.056,3.303,-1.4196299,-5.68847,-28494000,-17919376,-31952000,0.0,0.0,0.0,USD,
4,The Pennzoil Building,Suite 1300 North Tower 700 Milam,Houston,TX,77002,United States,410 350 1839,https://www.anthera.com,Biotechnology,Biotechnology,Healthcare,Healthcare,"Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.",21,"{'maxAge': 1, 'name': 'Joshua  Caldwell', 'title': 'Chief Liquidating Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1514678400,86400,4,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0001,0.0,-123.55394,-6.493506e-05,200,200,1121,6950,6950,617832,0.0001,0.008,0.000258,0.0001395,0.0,0.0,USD,-8083382,0.0,26133226,26179300,2015026,1428680,1526342400,1529020800,0.077,0.0,0.0,2.09,0.104499996,6178319872,0.209,0.00047846886,1514678400,1546214400,1522454400,-24931000,-0.01,-1.54,1:8,1493596800,0.222,0.0,0.14113986,PNK,EQUITY,ANTH,ANTH,ANTHERA PHARMACEUTICALS INC,"Anthera Pharmaceuticals, Inc.",1267453800,America/New_York,EDT,7c61d184-c1c3-38af-ae8a-007492657057,finmb_20805580,-14400000,0.0001,none,8086000,0.309,-36402000,0,3.056,3.303,-1.4196299,-5.68847,-28494000,-17919376,-31952000,0.0,0.0,0.0,USD,
